These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 14501049)

  • 41. Catalytic cleavage of cis- and trans-acting antigenomic delta ribozymes in the presence of various divalent metal ions.
    Wrzesinski J; Legiewicz M; Smólska B; Ciesiolka J
    Nucleic Acids Res; 2001 Nov; 29(21):4482-92. PubMed ID: 11691936
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ribozyme expression systems.
    Sano M; Taira K
    Methods Mol Biol; 2004; 252():195-207. PubMed ID: 15017050
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Functional gene discovery using hybrid ribozyme libraries.
    Kato Y; Tsunemi M; Miyagishi M; Kawasaki H; Taira K
    Methods Mol Biol; 2004; 252():245-56. PubMed ID: 15017054
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Secondary structure prediction and in vitro accessibility of mRNA as tools in the selection of target sites for ribozymes.
    Amarzguioui M; Brede G; Babaie E; Grotli M; Sproat B; Prydz H
    Nucleic Acids Res; 2000 Nov; 28(21):4113-24. PubMed ID: 11058107
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Engineering high-speed allosteric hammerhead ribozymes.
    Link KH; Guo L; Ames TD; Yen L; Mulligan RC; Breaker RR
    Biol Chem; 2007 Aug; 388(8):779-86. PubMed ID: 17655496
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fixation and accumulation of thermotolerant catalytic competence of a pair of ligase ribozymes through complex formation and cross ligation.
    Isomoto N; Maeda Y; Tanaka T; Furuta H; Ikawa Y
    J Mol Evol; 2013 Feb; 76(1-2):48-58. PubMed ID: 23288433
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cleavage of hepatitis B virus RNA by three ribozymes transcribed from a single DNA template.
    von Weizsäcker F; Blum HE; Wands JR
    Biochem Biophys Res Commun; 1992 Dec; 189(2):743-8. PubMed ID: 1472046
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expanding the catalytic repertoire of ribozymes and deoxyribozymes beyond RNA substrates.
    Franzen S
    Curr Opin Mol Ther; 2010 Apr; 12(2):223-32. PubMed ID: 20373266
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Computational design of allosteric ribozymes as molecular biosensors.
    Penchovsky R
    Biotechnol Adv; 2014; 32(5):1015-27. PubMed ID: 24877999
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeted cleavage: tuneable cis-cleaving ribozymes.
    Rossi JJ
    Proc Natl Acad Sci U S A; 2007 Sep; 104(38):14881-2. PubMed ID: 17855561
    [No Abstract]   [Full Text] [Related]  

  • 51. Inhibition of c-Ha-ras gene expression by hammerhead ribozymes containing a stable C(UUCG)G hairpin loop.
    Koizumi M; Kamiya H; Ohtsuka E
    Biol Pharm Bull; 1993 Sep; 16(9):879-83. PubMed ID: 8268855
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Catalytic strategies of the hepatitis delta virus ribozymes.
    Shih IH; Been MD
    Annu Rev Biochem; 2002; 71():887-917. PubMed ID: 12045114
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture.
    Bramlage B; Luzi E; Eckstein F
    Nucleic Acids Res; 2000 Nov; 28(21):4059-67. PubMed ID: 11058100
    [TBL] [Abstract][Full Text] [Related]  

  • 54. RNA reprogramming and repair based on trans-splicing group I ribozymes.
    Fiskaa T; Birgisdottir AB
    N Biotechnol; 2010 Jul; 27(3):194-203. PubMed ID: 20219714
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes.
    Kronenwett R; Haas R; Sczakiel G
    J Mol Biol; 1996 Jun; 259(4):632-44. PubMed ID: 8683570
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design and testing of ribozymes for cancer gene therapy.
    Norris JS; Hoel B; Voeks D; Maggouta F; Dahm M; Pan W; Clawson G
    Adv Exp Med Biol; 2000; 465():293-301. PubMed ID: 10810634
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Design and validation of therapeutic hammerhead ribozymes for autosomal dominant diseases.
    Fritz JJ; Gorbatyuk M; Lewin AS; Hauswirth WW
    Methods Mol Biol; 2004; 252():221-36. PubMed ID: 15017052
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transport of intracellularly active ribozymes to the cytoplasm.
    Miyagishi M; Kuwabara T; Taira K
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S96-101. PubMed ID: 11587376
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Use of a bacterial system of selection based on Bacillus subtilis for selecting mutant ribozymes that function effectively in vivo].
    Belzhelarskaia SN; Orlovskiĭ IV; Nikitenko SV
    Dokl Akad Nauk; 1996 Mar; 347(1):113-6. PubMed ID: 8768120
    [No Abstract]   [Full Text] [Related]  

  • 60. RNA double cleavage by a hairpin-derived twin ribozyme.
    Schmidt C; Welz R; Müller S
    Nucleic Acids Res; 2000 Feb; 28(4):886-94. PubMed ID: 10648779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.